Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma.
A group of 51 patients with multiple myeloma, non-Hodgkin's lymphoma or Hodgkin's disease receiving high-dose chemotherapy and autologous peripheral blood stem cell rescue received chemotherapy and clinical care in the peritransplant period at home. This group was compared with 88 cases with the same diagnoses, receiving the peripheral stem cell transplant over the same time period as an inpatient in a high efficiency particulate air filtered bone marrow transplant unit. Patients were treated at home based on choice, geographic accessibility, availability of an educated care giver and a clean home environment, and comprehension of the concepts of infection and aseptic techniques. Febrile neutropenia and sepsis were not increased in the home group and no episodes of septic shock were seen in this group. Patients at home received prophylactic oral ciprofloxacin and roxithromycin during the phase when the absolute neutrophil count was < 1 x 10(9)/l. Fewer gram-negative infections, but no diminution in gram-positive infections or in the rate of fever were seen in patients at home. Empiric therapy with a third generation cephalosporin, teicoplanin and tobramycin was instituted in 31 patients who developed a fever greater than 38.5 degrees C. Of this group of 31, 18 required admission to hospital, 12 because of febrile neutropenia which persisted or was considered unsuitable for management at home due to sepsis. The remaining 13 with febrile neutropenia remained at home throughout, as did the 20 cases not developing neutropenic fever. This study demonstrates the feasibility of managing carefully selected patients in their home environment when at risk from febrile neutropenia or other septic complications following autologous peripheral stem cell support.
Herrmann
R P
RP
Bone Marrow Transplant Unit, Royal Perth Hospital, Australia.
Trent
M
M
Cooney
J
J
Cannell
P K
PK
D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D003967:Diarrhea / Q000209:etiology; D004780:Environment, Controlled; D005334:Fever / Q000382:microbiology; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000150:complications; D006699:Home Care Services; D018575:Home Care Services, Hospital-Based; D006760:Hospitalization; D006801:Humans; D017053:Infection Control; D007239:Infections / Q000209:etiology; D008223:Lymphoma / Q000150:complications* / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000150:complications; D009101:Multiple Myeloma / Q000150:complications / Q000628:therapy; D015996:Survival Rate; D014182:Transplantation, Autologous
D000900:Anti-Bacterial Agents